Reduced brain volumes in mice expressing APP-Austrian mutation but not in mice expressing APP-Swedish–Austrian mutations

We previously described two transgenic mouse lines expressing sub-endogenous levels of the 'Austrian' APP-T714I mutation (driven by the prenatally active PDGF-beta promoter; APP-Au mice) and showing intraneuronal Abeta pathology and reduced brain volumes on MRI at 12 and 20 months of age. To further investigate whether reduced brain sizes were caused by neurodegeneration or a neurodevelopmental defect, we now measured brain volumes as early as postnatal day 10. At this age, a distinguishable reduction in brain volumes was absent, indicating that brain volume deficits in APP-Au mice are not caused by a neurodevelopmental defect. To further study the association between intraneuronal Abeta and reduced brain volumes, we further generated and analyzed an APP transgenic mouse model expressing both Austrian and Swedish (K670N/M671L) mutations (APP-SwAu mice). APP-Swedish mutation is known to lead to altered APP processing in the secretory pathway, precluding its later processing in endosomal-lysosomal compartments, the site of intraneuronal Abeta accumulation. Also, to have higher levels of transgene expression only after birth, a murine Thy-1 promoter was utilized for APP-SwAu mouse lines. Despite having five times higher transgene APP levels compared to APP-Au mice, APP-SwAu mice showed significantly lower intraneuronal Abeta levels in the absence of reduced brain volumes, suggesting that intraneuronal Abeta accumulation is related to reduced brain volumes in APP-Au mice. These data also provide a first in vivo indication of altered processing of APP-Swedish at sub-endogenous levels, an effect not observed in mouse models expressing the APP-Swedish mutation in high amounts.

[1]  C. Almeida,et al.  Intraneuronal Aβ accumulation and origin of plaques in Alzheimer's disease , 2005, Neurobiology of Aging.

[2]  T. Bayer,et al.  A modified β‐amyloid hypothesis: intraneuronal accumulation of the β‐amyloid peptide – the first step of a fatal cascade , 2004, Journal of neurochemistry.

[3]  Runsheng Wang,et al.  Wild-type Presenilin 1 Protects against Alzheimer Disease Mutation-induced Amyloid Pathology* , 2006, Journal of Biological Chemistry.

[4]  H. Vanderstichele,et al.  Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease. , 2000, Human molecular genetics.

[5]  A. Yang,et al.  Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Aβ1‐42 pathogenesis , 1998, Journal of neuroscience research.

[6]  Annemie Van der Linden,et al.  Intraneuronal amyloid β and reduced brain volume in a novel APP T714I mouse model for Alzheimer's disease , 2008, Neurobiology of Aging.

[7]  B. Strooper,et al.  Pathogenic APP mutations near the γ-secretase cleavage site differentially affect Aβ secretion and APP C-terminal fragment stability , 2001 .

[8]  P. Greengard,et al.  Intraneuronal Aβ42 Accumulation in Human Brain , 2000 .

[9]  Ling-gang Wu,et al.  Deletion of Presenilin 1 Hydrophilic Loop Sequence Leads to Impaired γ-Secretase Activity and Exacerbated Amyloid Pathology , 2006, The Journal of Neuroscience.

[10]  F. Shie,et al.  Early intraneuronal Aβ deposition in the hippocampus of APP transgenic mice , 2003 .

[11]  B. Strooper,et al.  Presenilin clinical mutations can affect γ‐secretase activity by different mechanisms , 2006, Journal of neurochemistry.

[12]  D. Campion,et al.  Unusual phenotypic alteration of β amyloid precursor protein (βAPP) maturation by a new Val-715 → Met βAPP-770 mutation responsible for probable early-onset Alzheimer’s disease , 1999 .

[13]  R. Essalmani,et al.  Missense mutations associated with familial Alzheimer's disease in Sweden lead to the production of the amyloid peptide without internalization of its precursor. , 1996, Biochemical and Biophysical Research Communications - BBRC.

[14]  Veerle Baekelandt,et al.  Early Phenotypic Changes in Transgenic Mice That Overexpress Different Mutants of Amyloid Precursor Protein in Brain* , 1999, The Journal of Biological Chemistry.

[15]  John Hardy,et al.  Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. , 2005, The American journal of pathology.

[16]  D. Selkoe,et al.  The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway , 1995, Nature Medicine.

[17]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  C. van Broeckhoven,et al.  Mean age‐of‐onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Aβ42 and decreased Aβ40 , 2006, Human mutation.

[19]  D. Selkoe,et al.  Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production , 1992, Nature.

[20]  R. Turner,et al.  ELISA analysis of β‐secretase cleavage of the Swedish amyloid precursor protein in the secretory and endocytic pathways , 2002, Journal of neurochemistry.

[21]  Makoto Hashimoto,et al.  Differential neuropathological alterations in transgenic mice expressing α‐synuclein from the platelet‐derived growth factor and Thy‐1 promoters , 2002, Journal of neuroscience research.

[22]  D. Dickson,et al.  Aβ40 Inhibits Amyloid Deposition In Vivo , 2007, The Journal of Neuroscience.

[23]  C. Duyckaerts,et al.  Subcellular topography of neuronal Abeta peptide in APPxPS1 transgenic mice. , 2004, The American journal of pathology.